COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00229437
Recruitment Status : Completed
First Posted : September 29, 2005
Last Update Posted : February 28, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine the efficacy and safety of TAK-128, once daily (QD), in treating subjects with diabetic peripheral neuropathy.

Condition or disease Intervention/treatment Phase
Diabetic Neuropathies Drug: TAK-128 Drug: Placebo Phase 2

Detailed Description:

Polyneuropathy is a frequent complication of diabetes; it affects most individuals after prolonged hyperglycemia, and diabetic neuropathy is very common in the developed world. Chronic, insidious, distal sensorimotor polyneuropathy with autonomic impairment is the most typical form of diabetic neuropathy. Less common, but more florid presentations include autonomic symptoms or painful neuropathy. Although many patients have no or relatively few symptoms, the chronic polyneuropathy and autonomic dysfunction predispose to neurotrophic foot ulceration; consequently, diabetes is the leading cause of amputation today.

Diabetic neuropathy is a dying-back polyneuropathy with distal degeneration of the longest nerve fibers advancing in a centripetal direction. Multiple histopathological changes are observed, but progressive fiber loss is the hallmark of diabetic polyneuropathy. Other important features include endothelial cell basement membrane thickening, segmental demyelination and remyelination, and axonal atrophy. Similar pathological changes are observed in type 1 and type 2 diabetes. The severity of neuropathy as indicated by the stage of nerve fiber loss determines the clinical, electrophysiological, and quantitative sensory threshold features of this disorder. The functional measures of electrophysiological and quantitative sensory thresholds reflect the morphological changes and the clinical features.

Diabetic polyneuropathy is etiologically related to prolonged hyperglycemia with multiple consequences. Although strict glycemic control prevents neuropathy in type 1 patients if maintained for many years, similar interventions in those with type 2 diabetes mellitus are less successful. Type 2 patients may have neuropathy with considerable nerve fiber loss at the time of diagnosis because of unsuspected hyperglycemia in preceding years. Reversal of established neuropathy with strict glycemic control is not certain to occur, even if maintained for many years. Co-morbid disease often interferes with strict management of type 2 diabetes. Even among those with type 1 diabetes, a minority of patients are successful in maintaining prolonged euglycemia.

TAK-128 is a novel synthetic compound being developed as a treatment for diabetic neuropathy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 343 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Three Doses of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy
Study Start Date : March 2005
Actual Primary Completion Date : May 2006
Actual Study Completion Date : May 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: TAK-128 5 mg QD Drug: TAK-128
TAK-128 5 mg, tablets, orally, once daily for up to 6 months.

Experimental: TAK-128 50 mg QD Drug: TAK-128
TAK-128 50 mg, tablets, orally, once daily for up to 6 months.

Experimental: TAK-128 100 mg QD Drug: TAK-128
TAK-128 100 mg, tablets, orally, once daily for up to 6 months.

Placebo Comparator: Placebo QD Drug: Placebo
TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.

Primary Outcome Measures :
  1. Change from Baseline in composite measure of maximal nerve conduction velocity (Nerve Conduction Studies). [ Time Frame: Week 24 or Final Visit ]

Secondary Outcome Measures :
  1. Change from Baseline in the electrophysiologic parameters for individual nerves, including amplitudes (Nerve Conduction Studies). [ Time Frame: Week 24 or Final Visit ]
  2. Change from Baseline in vibration perception threshold measurements (Quantitative Sensory Testing). [ Time Frame: Weeks 12, 24 or Final Visit ]
  3. Change from Baseline in pain scores (Short-Form McGill Pain Questionnaire). [ Time Frame: Weeks: 8, 12, 16, 20, 24 or Final Visit ]
  4. Change from Baseline in the neurological examination (Clinical Neurological Examination). [ Time Frame: Weeks 12, 24 or Final Visit ]
  5. Change from Baseline in quality of life index (SF-36 Health Survey). [ Time Frame: Weeks: 8, 12, 16, 20, 24 or Final Visit ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female subjects of childbearing potential must be nonpregnant, nonlactating and on an acceptable form of contraception.
  • The subject has fasting clinical laboratory evaluations within the normal reference range for the testing laboratory, or if not, the results must be deemed not clinically significant by the investigator prior to randomization.
  • The subject has type 1 or 2 diabetes mellitus using World Health Organization Criteria.
  • The subject has mild to moderate peripheral neuropathy defined as:

    • Clinical neuropathy score greater than or equal to 2.5 on the Michigan Neuropathy Screening Instrument.
    • Confirmed abnormality of at least 2 nerve conduction study velocity parameters as defined by the Neurological Core Laboratory.
    • Sural sensory nerve potential amplitude greater than or equal to 1 microvolt.
  • The subject's glycosylated hemoglobin is less than or equal to 10%.
  • The subject is on stable diabetic therapy for at least 3 months prior to randomization.
  • The subject is on stable pain medication for at least 6 weeks prior to randomization, if applicable.
  • The subject's creatinine level is less than or equal to 2 mg/dL or 176.8 umol/L.
  • The subject is willing to follow an American Diabetes Association or similar recommended dietary regimen.

Exclusion Criteria:

  • The subject has a history of other neuropathies due to causes other than diabetes such as alcohol abuse liver or renal disease, uremia, toxic exposure, genetic factors, inflammatory demyelinating diseases, monoclonal gammopathies; or endocrine, metabolic or nutritional disorders (included treated or untreated pernicious anemia).
  • The subject has clinical or electrophysiologic evidence of bilateral carpal tunnel syndrome.
  • The subject has a significant skin abnormality or ulcerative changes in their lower extremities.
  • The subject's body mass index is greater than 40 kg/m2.
  • The subject's systolic blood pressure is greater than 160 mm Hg or diastolic blood pressure is greater than 95 mm Hg.
  • The subject has a history of myocardial infarction, coronary angioplasty or bypass graft, unstable angina pectoris, transient ischemic attacks, significant electrocardiograms, or documented cerebrovascular accident within 6 months prior to Screening, or is New York Heart Association Functional Cardiac Classification III or IV.
  • The subject has an alanine aminotransferase level of greater than 1.5 times the upper limit of normal, active liver disease, or jaundice.
  • The subject has a significant, actively treated or unstable pulmonary, gastrointestinal, hepatic, hematologic, musculoskeletal, or endocrine (other than diabetes mellitus or stably treated hypothyroidism) disease.
  • The subject has a previous history of cancer, other than basal cell carcinoma, that has not been in remission for at least 5 years prior to the first dose of study drug.
  • The subject has taken lipoic acid, linolenic acid (primrose oil), inositol, topiramate, Acetyl-L-Carnitine, nerve growth factors, or capsaicin within 30 days prior to Screening.
  • The subject has any other serious disease or condition at Screening or at randomization that might affect life expectancy or make it difficult to successfully manage and follow the subject according to the protocol.
  • The subject has a history of drug abuse (defined as illicit drug use) or a history of alcohol abuse (defined as regular or daily consumption of more than 4 alcoholic drinks per day) within the past 2 years.
  • The subject has a known hypersensitivity to a compound related to TAK-128.
  • Subjects can not use any of the following prescription medications throughout the duration of the study, including:

    • Lipoic acid
    • Linolenic acid (primrose oil)
    • Inositol
    • Topiramate
    • Acetyl-L-Carnitine
    • Nerve growth factors
    • Capsaicin
  • The subject currently is participating in another investigational study or has participated in an investigational study within the past (30 days or 5 half lives, whichever is longer).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00229437

Layout table for location information
United States, Arizona
Mesa, Arizona, United States
Peoria, Arizona, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Huntington Beach, California, United States
La Jolla, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Northridge, California, United States
San Francisco, California, United States
Torrance, California, United States
Tustin, California, United States
United States, Florida
Aventura, Florida, United States
Fort Myers, Florida, United States
Hialeah, Florida, United States
Miami, Florida, United States
Palm Beach Gardens, Florida, United States
Plant City, Florida, United States
United States, Georgia
Decatur, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Louisiana
New Orleans, Louisiana, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Flint, Michigan, United States
United States, Missouri
St. Louis, Missouri, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
Elizabeth, New Jersey, United States
New Brunswick, New Jersey, United States
United States, New York
Buffalo, New York, United States
Staten Island, New York, United States
United States, North Carolina
Greenville, North Carolina, United States
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Pennsylvania
Morrisville, Pennsylvania, United States
United States, Texas
Dallas, Texas, United States
Houston, Texas, United States
San Antonio, Texas, United States
United States, Virginia
Norfolk, Virginia, United States
United States, Washington
Tacoma, Washington, United States
Canada, Alberta
Calgary, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Ontario
Kingston, Ontario, Canada
North Bay, Ontario, Canada
Sarina, Ontario, Canada
Canada, Quebec
Gatineau, Quebec, Canada
Laval, Quebec, Canada
Quebec, Canada
Sponsors and Collaborators
Layout table for investigator information
Study Director: Medical Director Takeda
Layout table for additonal information
Responsible Party: Takeda Identifier: NCT00229437    
Other Study ID Numbers: 01-04-TL-128-003
U1111-1128-5843 ( Registry Identifier: WHO )
First Posted: September 29, 2005    Key Record Dates
Last Update Posted: February 28, 2012
Last Verified: February 2012
Keywords provided by Takeda:
Diabetic Mononeuropathy
Diabetic Neuralgia
Mononeuropathy, Diabetic
Neuralgia, Diabetic
Diabetic Polyneuropathy
Drug Therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Diabetic Neuropathies
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases